Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Fig. 3

The prognostic power of a panel consisting of potentially four favorable prognostic markers, including high expression of CD8+ T-cells and FOXP3+ T-cells, low tumor expression of Ki67 and BRAF wildtype status is demonstrated. A highly significant increase in the proportion of long-term survivors in association with the increase from one to four favorable markers (Logistic regression, p = 0.003)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us